Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

528 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O'Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, Pollak MN. Pritchard KI, et al. Among authors: pollak mn. J Clin Oncol. 2011 Oct 10;29(29):3869-76. doi: 10.1200/JCO.2010.33.7006. Epub 2011 Sep 12. J Clin Oncol. 2011. PMID: 21911723 Clinical Trial.
Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29.
Chapman JA, Costantino JP, Dong B, Margolese RG, Pritchard KI, Shepherd LE, Gelmon KA, Wolmark N, Pollak MN. Chapman JA, et al. Among authors: pollak mn. Breast Cancer Res Treat. 2015 Sep;153(2):353-60. doi: 10.1007/s10549-015-3547-4. Epub 2015 Aug 15. Breast Cancer Res Treat. 2015. PMID: 26276354 Free PMC article. Clinical Trial.
Relapse-free survival of statistically standardized continuous RT-PCR estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2): NCIC CTG MA.14.
Chapman JA, Sgroi DC, Goss PE, Zarella E, Binns S, Zhang Y, Schnabel CA, Erlander MG, Pritchard KI, Han L, Badovinac-Crnjevic T, Shepherd LE, Pollak MN. Chapman JA, et al. Among authors: pollak mn. Breast Cancer Res Treat. 2016 May;157(1):101-8. doi: 10.1007/s10549-016-3806-z. Epub 2016 Apr 26. Breast Cancer Res Treat. 2016. PMID: 27116182 Clinical Trial.
Impact of baseline BMI and weight change in CCTG adjuvant breast cancer trials.
Yerushalmi R, Dong B, Chapman JW, Goss PE, Pollak MN, Burnell MJ, Levine MN, Bramwell VHC, Pritchard KI, Whelan TJ, Ingle JN, Shepherd LE, Parulekar WR, Han L, Ding K, Gelmon KA. Yerushalmi R, et al. Among authors: pollak mn. Ann Oncol. 2017 Jul 1;28(7):1560-1568. doi: 10.1093/annonc/mdx152. Ann Oncol. 2017. PMID: 28379421 Free PMC article.
Competing risks of death in younger and older postmenopausal breast cancer patients.
Chapman JA, Pritchard KI, Goss PE, Ingle JN, Muss HB, Dent SF, Vandenberg TA, Findlay B, Gelmon KA, Wilson CF, Shepherd LE, Pollak MN. Chapman JA, et al. Among authors: pollak mn. World J Clin Oncol. 2014 Dec 10;5(5):1088-96. doi: 10.5306/wjco.v5.i5.1088. World J Clin Oncol. 2014. PMID: 25493245 Free PMC article.
Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial.
DeCensi A, Puntoni M, Gandini S, Guerrieri-Gonzaga A, Johansson HA, Cazzaniga M, Pruneri G, Serrano D, Schwab M, Hofmann U, Mora S, Aristarco V, Macis D, Bassi F, Luini A, Lazzeroni M, Bonanni B, Pollak MN. DeCensi A, et al. Among authors: pollak mn. Breast Cancer Res Treat. 2014 Nov;148(1):81-90. doi: 10.1007/s10549-014-3141-1. Epub 2014 Sep 25. Breast Cancer Res Treat. 2014. PMID: 25253174 Free PMC article. Clinical Trial.
528 results